First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma (RCC): An international multi-center study.
Bibliographic record
Abstract
4529 Background: Adjuvant pembrolizumab significantly improved overall survival (OS) and is FDA-approved for adjuvant RCC treatment. However, there is a paucity of data on sequential treatment following recurrence after pembrolizumab or other immune-oncology (IO)-based therapies (PD-1 or PD-L1 inhibitors) administered in the adjuvant setting. Methods: This study included consecutive patients (pts) from 27 international centers who received adjuvant IO-based systemic RCC therapies. Safety and efficacy of subsequent systemic therapy regimens that included vascular endothelial growth factor-targeted therapies (VEGF-TT) or alternative IO-based therapies were evaluated. Progression-free survival (PFS) and OS from the time of systemic therapy initiation following adjuvant IO were estimated using the Kaplan-Meier method. Objective response rates (ORRs) were determined per RECIST 1.1 criteria. Treatment-related adverse events (trAEs) leading to treatment discontinuation, dose reduction, or steroid use were collected. Results: Among 144 pts who received adjuvant IO, median (Q1-Q3) age was 56 (50-64) years, and 105 (73%) were males. Most pts had clear cell RCC (n=130, 90%), underwent radical nephrectomy (n=136, 94%), and had high or intermediate-high risk disease (n=129, 90%) per KEYNOTE-564 risk groups. Tumors of 15 (10%) pts had sarcomatoid features. Most pts received adjuvant pembrolizumab (n=74, 51%), atezolizumab (n=40, 28%), or nivolumab plus ipilimumab combination therapy (n=16, 11%). Most common reasons for adjuvant IO cessation were treatment completion (n=65, 45%), recurrence (n=36, 25%), or toxicity (n=34, 24%). RCC did not recur in 52 (36%) pts who remained under observation, whereas 92 (64%) had recurrent disease. Following tumor recurrence, 69/92 (75%) pts received systemic therapy; the remaining 25% underwent surgery or radiotherapy. Median follow-up from systemic therapy initiation was 16.7 months. Median PFS was 16 months (95% CI = 10.4 – 41.7), and 18-month OS was 86% (95%CI: 76.4 – 97.3%). ORR was 36% (n = 25/69). Most pts received VEGF-TT (n=32, 46%), IO/VEGF-TT combinations (n=21, 30%), or single/combination IO (n=12, 17%). ORRs were comparable (35% in VEGF-TT monotherapy, 45% in IO/VEGF-TT combination, 42% in single/combination IO cohort). In 23 pts who received adjuvant pembrolizumab monotherapy and subsequent systemic therapy, ORR was 44% (4/9) vs. 29% (4/14) for those recurring after vs. prior to discontinuation of pembrolizumab, respectively. Two out of 8 pts who discontinued adjuvant IO due to toxicity were rechallenged with subsequent IO and had stable disease, and one of them developed an immune-related AE. TrAEs occurred in 28/69 (41%) pts treated with subsequent systemic therapy. Conclusions: Patients with RCC who recur on or after adjuvant IO treatment benefit from subsequent systemic therapies across different regimens.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".